PT  - JOURNAL ARTICLE
AU  - Deakin, Bill
AU  - Liddle, Elizabeth
AU  - Rathnaiah, Mohanbabu
AU  - Gregory, Cathy
AU  - Katshu, Mohammad
AU  - Williams, Gemma
AU  - Conen, Silke
AU  - Smallman, Richard
AU  - Koelewijn, Loes C.
AU  - Anton, Adriana
AU  - Kumar, Jyothika
AU  - Gasgoyne, Lauren E.
AU  - Chen, Chen
AU  - Nikkheslat, Naghmeh
AU  - Evans, John
AU  - Lanz, Bernard
AU  - Walters, James
AU  - Talbot, Peter
AU  - Palaniyappan, Lena
AU  - Singh, Krish D.
AU  - Morris, Peter
AU  - Williams, Steven R.
AU  - Liddle, Peter F.
TI  - Defining the disturbance in cortical glutamate and GABA function in psychosis and its origins and consequences
AID  - 10.1101/2024.06.26.24308831
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.06.26.24308831
4099  - http://medrxiv.org/content/early/2024/06/27/2024.06.26.24308831.short
4100  - http://medrxiv.org/content/early/2024/06/27/2024.06.26.24308831.full
AB  - It is widely thought that the onset of psychotic symptoms in schizophrenia may arise from an early neurotoxic phase, possibly related to oxidative stress or inflammation, and a late residual damage phase associated with persistent negative symptoms. We tested this hypothesis in a 3-centre study using magnetic resonance spectroscopy (MRS) to determine whether abnormalities in glutamate, glutamine and GABA content in anterior cingulate cortex (ACC) differed between people with minimally treated ‘Recent’ onset schizophrenia and an ‘Established’ group with > 10 years of treatment. We tested whether neurochemical abnormalities were i) mediated by raised circulating inflammatory cytokine concentrations, c-reactive protein (CRP) and interleukin-6 (IL-6), or depletion of glutathione and ii) associated with ratings of positive and negative symptoms. Relative to age-matched controls, the Established group showed significantly greater reduction in ACC glutamate than the Recent group, which did not differ from controls. This effect was not attributable to antipsychotic drug exposure. Patient ACC glutathione was negatively correlated with age. IL-6 was increased in both clinical groups, while increases in CRP were greater in the Established than Recent group. Elevated CRP was entirely accounted for by greater antipsychotic drug exposure and BMI, while residual elevation in IL-6 in the Established group did not account for their lower ACC glutamate. GABA was reduced relative to controls across ACC and occipital voxels. This reduction was not associated with drug treatment, BMI or cytokine levels. Only ACC GABA content correlated significantly with symptoms, lower content with greater positive and negative symptoms across both groups.Competing Interest StatementLP reports personal fees for serving as chief editor from the Canadian Medical Association Journals, speaker/consultant fee from Janssen Canada and Otsuka Canada, SPMM Course Limited, UK, Canadian Psychiatric Association; book royalties from Oxford University Press; investigator-initiated educational grants from Janssen Canada, Sunovion and Otsuka Canada outside the submitted work.Funding StatementThis project was funded by Medical Research Council Experimental Medicine Challenge Full Grant (MR/K020803/ 1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The National Research Ethics Service Committe Northwest - Lancaster UK gave ethical approval for this work. Reference 14/NW/0298, Approval date 18/06/2014I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe database for this study database will be made available on reasonable request to bill.deakin{at}manchester.ac.uk